Biophytis Completes €2.6 Million Private Placement

Biophytis, a biotechnology firm specializing in age-related treatments, has successfully completed a €2.6 million private placement. The capital was raised through the issuance of 4,307,614 new shares at €0.26 each and 5,692,308 pre-funded warrants at €0.25 each, with attached share warrants. Armistice contributed €2 million, while qualified investors added €0.6 million.

The funds will support the advancement of Biophytis' clinical programs, specifically BIO101 in obesity and sarcopenia. The issuance was carried out without a prospectus approval, as per French market regulations, and was set on March 25, 2025.

Following this increase, the company's share capital could increase significantly upon the exercise of all warrants. Trading of the new shares is expected to commence on March 28, 2025, on Euronext Growth Paris.